KRAS and non-small cell lung carcinoma: Discordance of mutational status in primary and metastatic lesions has been shown to be as high as 28% and 24% in EGFR and KRAS, respectively, in a cohort of 25 patients with stage IV non-small-cell lung cancers (NSCLC) [36].